drugset
drugset / Trial / NCT05295121

Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets

NCT05295121 ↗

Phase 1 Completed 24 enrolled Valenta Pharm JSC
RandomizedCrossoverOpen-labelTreatment

Summary

Primary objective of the study: evaluation of the effect of food intake on the bioavailability of XC221 100 mg tablets after a single oral administration in fed or fasted condition. Additional objective of the study: evaluation of pharmacokinetic parameters, safety and tolerability of XC221 100 mg tablets in healthy volunteers after single oral administration in fed or fasted condition.

Timeline

Start
2022-02-10
Primary completion
2022-02-22
Completion
2022-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject XC221 Unknown 100 mg Oral

Indications

No indication recorded.